Page last updated: 2024-09-03
l 158809 and wl 19
l 158809 has been researched along with wl 19 in 1 studies
Compound Research Comparison
| Studies (l 158809) | Trials (l 158809) | Recent Studies (post-2010) (l 158809) | Studies (wl 19) | Trials (wl 19) | Recent Studies (post-2010) (wl 19) |
|---|---|---|---|---|---|
| 137 | 0 | 7 | 13 | 0 | 2 |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Chakravarty, PK; Chang, RS; Greenlee, WJ; Lotti, VJ; Mantlo, NB; Ondeyka, DL; Patchett, AA; Siegl, PK; Sweet, CS | 1 |
Other Studies
1 other study(ies) available for l 158809 and wl 19
| Article | Year |
|---|---|
In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist.
Topics: Administration, Oral; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Female; Imidazoles; Injections, Intravenous; Losartan; Macaca mulatta; Male; Pressoreceptors; Pyridines; Rats; Rats, Inbred Strains; Tetrazoles | 1992 |